Unknown

Dataset Information

0

Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.


ABSTRACT:

Unlabelled

Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.

Clinical trials registration

NCT 01543958.

SUBMITTER: Sandler NG 

PROVIDER: S-EPMC4215074 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.

Sandler Netanya G NG   Zhang Xinyan X   Bosch Ronald J RJ   Funderburg Nicholas T NT   Choi Andrew I AI   Robinson Janet K JK   Fine Derek M DM   Coombs Robert W RW   Jacobson Jeffrey M JM   Landay Alan L AL   Douek Daniel C DC   Tressler Randall R   Read Sarah W SW   Wilson Cara C CC   Deeks Steven G SG   Lederman Michael M MM   Gandhi Rajesh T RT  

The Journal of infectious diseases 20140526 10


<h4>Unlabelled</h4>Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial  ...[more]

Similar Datasets

| S-EPMC11308466 | biostudies-literature
| S-EPMC7350759 | biostudies-literature
| S-EPMC7488761 | biostudies-literature
| S-EPMC4116808 | biostudies-literature
| S-EPMC3138874 | biostudies-literature
| S-EPMC3569505 | biostudies-literature
| S-EPMC5294767 | biostudies-literature
| S-EPMC10320027 | biostudies-literature
| S-EPMC7287307 | biostudies-literature
| S-EPMC6085951 | biostudies-literature